Christopher M. Tipton

Nov 28, 2024 | cell.com | Caterina E. Faliti |Jinyong Choi |Simon Belanger |Christopher M. Tipton |Sakeenah L. Hicks |Maria Cardenas | +17 more

KeywordsantibodiesvaccineCD4 T cellsT follicular helper cellsTfh cellsplasma cellsIL-2 cytokinemTORmetabolismGet full text accessLog in, subscribe or purchase for full access. References1. Radbruch, A. ∙ Muehlinghaus, G. ∙ Luger, E.O. ... Competence and competition: the challenge of becoming a long-lived plasma cellNat. Rev. Immunol. 2006; 6:741-7502. Slifka, M.K. ∙ Antia, R. ∙ Whitmire, J.K. ... Humoral immunity due to long-lived plasma cellsImmunity. 1998; 8:363-3723.

Jun 16, 2023 | frontiersin.org | Eliver Ghosn |Christopher M. Tipton |Matthew Woodruff

IntroductionRheumatoid arthritis (RA) is the commonest autoimmune mediated inflammatory arthritis, affecting 1% of the world’s population. As well as chronic, severe pain and early joint destruction, patients experience marked fatigue, accelerated cardiovascular disease and premature death (1, 2). Despite the heterogenous clinical presentation, the importance of pathogenic B cells has been established and further reinforced by the success of B cell depleting therapies (BCDT) (3, 4).